journal
Journals Neurology® Neuroimmunology ...

Neurology® Neuroimmunology & Neuroinflammation

https://read.qxmd.com/read/38547427/disease-modifying-treatments-for-multiple-sclerosis-affect-measures-of-cellular-immune-responses-to-ebna-1-peptides
#21
JOURNAL ARTICLE
Lara Dungan, Jean Dunne, Michael Savio, Marianna Kalaszi, Matt McElheron, Yvonne Lynagh, Kate O'Driscoll, Carmel Roche, Ammara Qureshi, Brendan Crowley, Niall Conlon, Hugh Kearney
BACKGROUND AND OBJECTIVES: Epstein-Barr virus (EBV) has been strongly implicated in the pathogenesis of multiple sclerosis (MS). Despite this, there are no routinely used tests to measure cellular response to EBV. In this study, we analyzed the cellular response to EBV nuclear antigen-1 (EBNA-1) in people with MS (pwMS) using a whole blood assay. METHODS: This cross-sectional study took place in a dedicated MS clinic in a university hospital. We recruited healthy controls, people with epilepsy (PWE), and pwMS taking a range of disease-modifying treatments (DMTs) including natalizumab, anti-CD20 monoclonal antibodies (mAbs), dimethyl fumarate (DMF), and also treatment naïve...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38507658/complement-activation-is-associated-with-disease-severity-in-multiple-sclerosis
#22
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38507657/multiple-sclerosis-rituximab-hypogammaglobulinemia-and-risk-of-infections
#23
JOURNAL ARTICLE
Annette Langer-Gould, Bonnie H Li, Jessica B Smith, Stanley Xu
BACKGROUND AND OBJECTIVES: B-cell-depleting therapies increase the risk of infections and hypogammaglobulinemia. These relationships are poorly understood. The objectives of these analyses were to estimate how much of this rituximab-associated infection risk is mediated by hypogammaglobulinemia and to identify other modifiable risk factors in persons with multiple sclerosis (pwMS). METHODS: We conducted a retrospective cohort study of rituximab-treated pwMS from January 1, 2008, to December 31, 2020, in Kaiser Permanente Southern California...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38507656/functional-signature-of-lrp4-antibodies-in-myasthenia-gravis
#24
JOURNAL ARTICLE
Omar Chuquisana, Frauke Stascheit, Christian W Keller, Maja Pučić-Baković, Anne-Marie Patenaude, Gordan Lauc, Socrates Tzartos, Heinz Wiendl, Nick Willcox, Andreas Meisel, Jan D Lünemann
BACKGROUND AND OBJECTIVES: Antibodies (Abs) specific for the low-density lipoprotein receptor-related protein 4 (LRP4) occur in up to 5% of patients with myasthenia gravis (MG). The objective of this study was to profile LRP4-Ab effector actions. METHODS: We evaluated the efficacy of LRP4-specific compared with AChR-specific IgG to induce Ab-dependent cellular phagocytosis (ADCP), Ab-dependent cellular cytotoxicity (ADCC), and Ab-dependent complement deposition (ADCD)...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38484219/impact-of-immune-checkpoint-inhibitors-on-the-course-of-multiple-sclerosis
#25
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38484218/immune-checkpoint-inhibitor-associated-kelch-like-protein-11-igg-brainstem-encephalitis
#26
JOURNAL ARTICLE
Albert Aboseif, Nisa Vorasoot, Marcus V Pinto, Yong Guo, Shemonti Hasan, Anastasia Zekeridou, John J Chen, Divyanshu Dubey
OBJECTIVES: Kelch-like protein-11 (KLHL11)-IgG is associated with rhombencephalitis and seminoma. It has not previously been described as a neurologic immune checkpoint inhibitor (ICI)-related adverse event (nirAE) or in association with esophageal adenocarcinoma. METHODS: We describe a 61-year-old man with metastatic esophageal adenocarcinoma treated with folinic acid, fluorouracil, oxaliplatin (FOLFOX), and nivolumab, who subsequently developed diplopia, vertigo, and progressive gait ataxia after 8 weeks of treatment...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38484217/membrane-proteome-wide-screening-of-autoantibodies-in-cidp-using-human-cell-microarray-technology
#27
JOURNAL ARTICLE
Marta Caballero-Ávila, Cinta Lleixà, Elba Pascual-Goñi, Lorena Martín-Aguilar, Núria Vidal-Fernandez, Clara Tejada-Illa, Roger Collet-Vidiella, Ricardo Rojas-Garcia, Elena Cortés-Vicente, Janina Turon-Sans, Eduard Gallardo, Montse Olivé, Ana Vesperinas, Álvaro Carbayo, Laura Llansó, Laura Martinez-Martinez, Anthony Shock, Louis Christodoulou, Benjamin Dizier, Jim Freeth, Jo Soden, Sarah Dawson, Luis Querol
BACKGROUND AND OBJECTIVES: Autoantibody discovery in complex autoimmune diseases is challenging. Diverse successful antigen identification strategies are available, but, so far, have often been unsuccessful, especially in the discovery of protein antigens in which conformational and post-translational modification are critical. Our study assesses the utility of a human membrane and secreted protein microarray technology to detect autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38386951/progressive-encephalomyelopathy-in-an-older-man-a-case-report-from-the-national-multiple-sclerosis-society-case-conference-proceedings
#28
REVIEW
Lindsay A Ross, Jonathan Lee, Alise K Carlson, Devon S Conway, Jeffrey A Cohen, Jennifer Graves, Scott S Zamvil, Scott D Newsome, Amy Kunchok
We present a case of subacute onset progressive encephalomyelopathy in a 77-year-old man with symmetric lateral column signal abnormalities on spinal MRI. We discuss the differential and presumptive final diagnosis along with a review of the postulated disease immunopathogenesis.
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38364193/clinical-characterization-and-ancillary-tests-in-susac-syndrome-a-systematic-review
#29
REVIEW
Adi Wilf-Yarkoni, Ofir Zmira, Assaf Tolkovsky, Barak Pflantzer, Shany G Gofrit, Ilka Kleffner, Friedemann Paul, Jan Dörr
Susac syndrome (SuS) is an orphan microangiopathic disease characterized by a triad of encephalopathy, visual disturbances due to branch retinal artery occlusions, and sensorineuronal hearing loss. Our previous systematic review on all cases of SuS reported until 2012 allowed for a better understanding of clinical presentation and diagnostic findings. Based on these data, we suggested diagnostic criteria in 2016 to allow early diagnosis and treatment of SuS. In view of the accumulation of new SuS cases reported in the last 10 years and improved diagnostic tools, we here aimed at updating the demographic and clinical features of SuS and to review the updated ancillary tests being used for SuS diagnosis...
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38285968/a-42-year-old-woman-with-rapidly-expanding-white-matter-lesions-from-the-national-multiple-sclerosis-society-case-conference-proceedings
#30
JOURNAL ARTICLE
Tolulope O Amiola, Unsong Oh, Hope Richard, Scott D Newsome, Jennifer Graves, Scott S Zamvil, Myla D Goldman
A 42-year-old woman and active cocaine user complained of subacutely worsening blurred vision and imbalance. Examination of the brain MRI showed rapidly expanding white matter lesions. Brain biopsy was consistent with inflammatory demyelination. Given an unusual presentation and a history of cocaine use, a broad differential diagnosis was considered including neurologic toxidromes.
May 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38359385/autoantibodies-against-dihydrolipoamide-s-acetyltransferase-in-immune-mediated-neuropathies
#31
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38354323/complement-activation-is-associated-with-disease-severity-in-multiple-sclerosis
#32
JOURNAL ARTICLE
Johanna Oechtering, Kerstin Stein, Sabine A Schaedelin, Aleksandra M Maceski, Annette Orleth, Stephanie Meier, Eline Willemse, Ferhan Qureshi, Ingmar Heijnen, Axel Regeniter, Tobias Derfuss, Pascal Benkert, Marcus D'Souza, Marguerite Limberg, Bettina Fischer-Barnicol, Lutz Achtnichts, Stefanie Mueller, Anke Salmen, Patrice H Lalive, Claire Bridel, Caroline Pot, Renaud A Du Pasquier, Claudio Gobbi, Heinz Wiendl, Cristina Granziera, Ludwig Kappos, Marten Trendelenburg, David Leppert, Jan D Luenemann, Jens Kuhle
BACKGROUND AND OBJECTIVES: Histopathologic studies have identified immunoglobulin (Ig) deposition and complement activation as contributors of CNS tissue damage in multiple sclerosis (MS). Intrathecal IgM synthesis is associated with higher MS disease activity and severity, and IgM is the strongest complement-activating immunoglobulin. In this study, we investigated whether complement components (CCs) and complement activation products (CAPs) are increased in persons with MS, especially in those with an intrathecal IgM synthesis, and whether they are associated with disease severity and progression...
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38350048/chronic-active-lesions-and-larger-choroid-plexus-explain-cognition-and-fatigue-in-multiple-sclerosis
#33
JOURNAL ARTICLE
Paolo Preziosa, Elisabetta Pagani, Alessandro Meani, Loredana Storelli, Monica Margoni, Yury Yudin, Nicolò Tedone, Diana Biondi, Martina Rubin, Maria A Rocca, Massimo Filippi
BACKGROUND AND OBJECTIVES: Chronic inflammation may contribute to cognitive dysfunction and fatigue in patients with multiple sclerosis (MS). Paramagnetic rim lesions (PRLs) and choroid plexus (CP) enlargement have been proposed as markers of chronic inflammation in MS being associated with a more severe disease course. However, their relation with cognitive impairment and fatigue has not been fully explored yet. Here, we investigated the contribution of PRL number and volume and CP enlargement to cognitive impairment and fatigue in patients with MS...
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38350043/cd11c-high-b-cell-expansion-is-associated-with-severity-and-brain-atrophy-in-neuromyelitis-optica
#34
JOURNAL ARTICLE
Eiichiro Amano, Wakiro Sato, Yukio Kimura, Atsuko Kimura, Youwei Lin, Tomoko Okamoto, Noriko Sato, Takanori Yokota, Takashi Yamamura
BACKGROUND AND OBJECTIVES: Neuromyelitis optica (NMO) is an autoimmune astrocytopathy mediated by anti-AQP4 antibody-producing B cells. Recently, a B-cell subset highly expressing CD11c and T-bet, originally identified as age-associated B cells, has been shown to be involved in the pathogenesis of various autoimmune diseases. The objective of this study was to determine the relationship between the frequency of CD11chigh B cells per CD19+ B cells in the peripheral blood of patients with NMO and the clinical profiles including the brain volume...
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38346270/cxcl10-igg1-axis-in-multiple-sclerosis-as-a-potential-predictive-biomarker-of-disease-activity
#35
JOURNAL ARTICLE
Nora Welsh, Krista Disano, Michael Linzey, Steven C Pike, Andrew D Smith, Andrew R Pachner, Francesca Gilli
BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is a heterogeneous disease, and its course is difficult to predict. Prediction models can be established by measuring intrathecally synthesized proteins involved in inflammation, glial activation, and CNS injury. METHODS: To determine how these intrathecal proteins relate to the short-term, i.e., 12 months, disease activity in relapsing-remitting MS (RRMS), we measured the intrathecal synthesis of 46 inflammatory mediators and 14 CNS injury or glial activation markers in matched serum and CSF samples from 47 patients with MS (pwMS), i...
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38346268/impact-of-immune-checkpoint-inhibitors-on-the-course-of-multiple-sclerosis
#36
JOURNAL ARTICLE
Géraldine Androdias, Louise Noroy, Dimitri Psimaras, Cristina Birzu, Jean Pelletier, Ysoline Beigneux, Pierre Branger, Jonathan Ciron, Yannick Dananchet, Raphael Depaz, Caroline Froment Tilikete, Laurence Gignoux, Clara Grosset-Janin, Bastien Joubert, Philippe Kerschen, Arnaud Kwiatkowski, Christine Lebrun-Frenay, Elisabeth Maillart, Aurelien Maureille, Philippe Nicolas, Thomas Roux, Romain Marignier, Sandra Vukusic
OBJECTIVES: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment. Their mechanism of action raises the question of possible exacerbation of preexisting multiple sclerosis (MS). The aim of our study was to assess the risk of increased MS activity, defined by the occurrence of a relapse and/or a new MRI lesion, after ICI initiation. METHODS: This French multicentric study collected retrospective and prospective data on patients with MS treated with ICIs after a cancer diagnosis...
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38315937/neurologic-syndromes-related-to-anti-gad65-clinical-and-serologic-response-to-treatment
#37
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38266211/absence-of-systemic-oxidative-stress-and-increased-csf-prostaglandin-f2%C3%AE-in-progressive-ms
#38
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38215349/glycine-receptor-%C3%AE-targeting-autoantibodies-contribute-to-the-pathology-of-autoimmune-diseases
#39
JOURNAL ARTICLE
Anna-Lena Wiessler, Ivan Talucci, Inken Piro, Sabine Seefried, Verena Hörlin, Betül B Baykan, Erdem Tüzün, Natascha Schaefer, Hans M Maric, Claudia Sommer, Carmen Villmann
BACKGROUND AND OBJECTIVES: Stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM) are rare neurologic disorders of the CNS. Until now, exclusive GlyRα subunit-binding autoantibodies with subsequent changes in function and surface numbers were reported. GlyR autoantibodies have also been described in patients with focal epilepsy. Autoimmune reactivity against the GlyRβ subunits has not yet been shown. Autoantibodies against GlyRα1 target the large extracellular N-terminal domain...
March 2024: Neurology® Neuroimmunology & Neuroinflammation
https://read.qxmd.com/read/38207017/neuropsychological-testing-in-autoimmune-encephalitis-a-scoping-review
#40
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 2024: Neurology® Neuroimmunology & Neuroinflammation
journal
journal
49467
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.